📰 Human Use News
Page 102 - Human Use News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Human Use. Real-time updates on events, politics, business and more.
December 8, 2022
The European Commission Approved QDENGA (TAK-003) for Use in Individuals Four Years of Age and Olderi QDENGA Becomes the Only Dengue Vaccine Approved in the EU for Use in Individuals Regardless of Previous
December 8, 2022
Takeda’s QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
December 7, 2022
Comirnaty® has been authorised by the MHRA as a Covid-19 vaccine for individuals from six months to four years old.
December 6, 2022
The Comirnaty COVID vaccine has met the MHRA’s required safety, quality and effectiveness standards to be authorised for use in this age group
December 5, 2022
The European Medicines Agency (EMA) has validated GSK’s marketing authorization application (MAA) for momelotinib to treat myelofibrosis.
December 5, 2022
Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who have been treated
December 5, 2022
The marketing authorisation application for momelotinib, a new oral treatment for myelofibrosis has been accepted by the EMA.
December 2, 2022
LONDON (dpa-AFX) - GSK plc (GSK.L, GSK) said Friday that the European Medicines Agency has accepted the marketing authorization application for momelotinib for the treatment of myelofibrosis.The
November 29, 2022
Innovative Presentation Developed in Partnership with Medical Products LeaderROSEMONT, Ill., Nov. 29, 2022 /PRNewswire/ -- Capstone Development Se...
November 28, 2022
MMV and Shin Poong Pharm. Co., Ltd. welcome the formal inclusion of Pyramax® (pyronaridine-artesunate) in the World Health Organization’s (WHO) Guidelines for Malaria (http://bit.ly/3EZSJep) following an extensive review process. The WHO’s Guidelines for the Treatment